Martha A Sedegah, Age 73347 Parkview Ave, Gaithersburg, MD 20878
Martha Sedegah Phones & Addresses
347 Parkview Ave APT 116, Gaithersburg, MD 20878 (301) 963-0048
402 Deer Park Rd, Gaithersburg, MD 20877 (301) 840-0406 (301) 869-2933 (301) 963-0048
Redwood City, CA
Rockville, MD
347 Parkview Ave, Gaithersburg, MD 20878 (301) 840-0406
Work
Position:
Sales Occupations
Education
Degree:
Associate degree or higher
Mentions for Martha A Sedegah
Publications & IP owners
Us Patents
Malaria Antigen Screening Method
US Patent:
8450055, May 28, 2013
Filed:
Aug 25, 2006
Appl. No.:
11/513439
Inventors:
Joseph T. Bruder - Ijamsville MD, US
Imre Kovesdi - Rockville MD, US
Duncan L. McVey - Derwood MD, US
Douglas E. Brough - Gaithersburg MD, US
C. Richter King - Washington DC, US
Denise Louise Doolan - Camp Hill, AU
Joao Carlos Aguair - Potomac MD, US
Daniel John Carucci - Washington DC, US
Martha Sedegah - Gaithersburg MD, US
Walter R. Weiss - Bethesda MD, US
Keith Limbach - Gaithersburg MD, US
Imre Kovesdi - Rockville MD, US
Duncan L. McVey - Derwood MD, US
Douglas E. Brough - Gaithersburg MD, US
C. Richter King - Washington DC, US
Denise Louise Doolan - Camp Hill, AU
Joao Carlos Aguair - Potomac MD, US
Daniel John Carucci - Washington DC, US
Martha Sedegah - Gaithersburg MD, US
Walter R. Weiss - Bethesda MD, US
Keith Limbach - Gaithersburg MD, US
Assignee:
The United States of America as Represented by the Secretary of the Navy - Washington DC
International Classification:
C12Q 1/70
C12N 1/10
A61K 39/00
A61K 39/38
A61K 39/015
C40B 40/02
C40B 50/06
C12N 1/10
A61K 39/00
A61K 39/38
A61K 39/015
C40B 40/02
C40B 50/06
US Classification:
435 5, 4352582, 4241841, 4242681, 4242721, 506 14, 506 26
Abstract:
The invention provides a method of identifying an antigen from a pathogen or a disease antigen comprising the use of an adenoviral vector array comprising two or more different adenoviral vectors, wherein each adenoviral vector comprises a nucleic acid sequence encoding a different antigen of a pathogen. The adenoviral vectors are administered to antigen presenting cells (APCs) in vitro or to an animal in vivo. The immunogenicity of the antigen is measured by screening for an immune response from effector T lymphocytes in vitro and by screening for the absence of pathogen-induced disease onset in vivo.
Plasmodium Falciparum Hla Class I Restricted T-Cell Epitopes
US Patent:
2011011, May 19, 2011
Filed:
Nov 9, 2010
Appl. No.:
12/942103
Inventors:
Martha Sedegah - Gaithersburg MD, US
Thomas Richie - Glenelg MD, US
Thomas Richie - Glenelg MD, US
International Classification:
A61K 39/002
G01N 33/53
A61P 37/04
A61P 33/06
G01N 33/53
A61P 37/04
A61P 33/06
US Classification:
4241911, 435 724
Abstract:
The invention relates immunogenic polypeptides and epitopes from protein AMA1. The epitopes contain HLA class I binding motifs and stimulate an anti-malaria CD8T-cell response. The polypeptides can be incorporated into immunogenic formulations against malaria. Additionally, the antigens are useful for facilitating evaluation of immunogenicity of candidate malaria vaccines.
Polynucleotide Vaccine Protective Against Malaria, Methods Of Protection And Vector For Delivering Polynucleotide Vaccines
US Patent:
6066623, May 23, 2000
Filed:
Nov 23, 1993
Appl. No.:
8/155888
Inventors:
Stephen L. Hoffman - Gaithersburg MD
Richard C. Hedstrom - Gaithersburg MD
Martha Sedegah - Gaithersburg MD
Richard C. Hedstrom - Gaithersburg MD
Martha Sedegah - Gaithersburg MD
Assignee:
The United States of America as represented by the Secretary of the Navy - Washington DC
International Classification:
A61K 4800
C12N 500
C12N 1500
C12N 500
C12N 1500
US Classification:
514 44
Abstract:
A first embodiment is a specific plasmid vector, pDIP/PyCSP. 1, into which nucleotides encoding the targets of specific immune responses are inserted. These targets include, but are not limited to proteins and peptides. These plasmid constructs are incorporated in a composition comprising a suitable and acceptable art recognized pharmaceutical reagent that is benign (non-reactive with) to the plasmid construct. The plasmid construct provides protective immune responses to the disease associated with the selected targets. A second embodiment is a construct having, at a minimum, the nucleotide sequences encoding one or more Plasmodium species proteins in a pharmaceutically acceptable vector. a third embodiment is a method of controlling malaria in mammals comprising injecting a polynucleotide delivery vector into a mammal.
Malaria Antigen Screening Method
US Patent:
2017021, Aug 3, 2017
Filed:
Apr 10, 2017
Appl. No.:
15/483427
Inventors:
- Silver Spring MD, US
Imre Kovesdi - Rockville, HU
Duncan L. McVey - Derwood MD, US
Douglas E. Brough - Gaithersburg MD, US
Richter C. King - Washington DC, US
Denise L. Doolan - Camp Hill, AU
Joao C. Aguair - Potomac MD, US
Daniel J. Carucci - Washington DC, US
Martha Sedegah - Gaithersburg MD, US
Walter R. Weiss - Bethesda MD, US
Keith Limbach - Gaithersburg MD, US
Imre Kovesdi - Rockville, HU
Duncan L. McVey - Derwood MD, US
Douglas E. Brough - Gaithersburg MD, US
Richter C. King - Washington DC, US
Denise L. Doolan - Camp Hill, AU
Joao C. Aguair - Potomac MD, US
Daniel J. Carucci - Washington DC, US
Martha Sedegah - Gaithersburg MD, US
Walter R. Weiss - Bethesda MD, US
Keith Limbach - Gaithersburg MD, US
Assignee:
United States of America as Represented by the Secretary of the Navy - Silver Spring MD
International Classification:
G01N 33/50
A61K 49/00
C12N 7/00
G01N 33/574
G01N 33/564
C12N 15/10
G01N 33/569
A61K 39/015
A61K 49/00
C12N 7/00
G01N 33/574
G01N 33/564
C12N 15/10
G01N 33/569
A61K 39/015
Abstract:
The invention provides a method of identifying an antigen from a pathogen or a disease antigen comprising the use of an adenoviral vector array comprising two or more different adenoviral vectors, wherein each adenoviral vector comprises a nucleic acid sequence encoding a different antigen of a pathogen. The adenoviral vectors are administered to antigen presenting cells (APCs) in vitro or to an animal in vivo. The immunogenicity of the antigen is measured by screening for an immune response from effector T lymphocytes in vitro and by screening for the absence of pathogen-induced disease onset in vivo.
Malaria Antigen Screening Method
US Patent:
2017008, Mar 23, 2017
Filed:
Apr 19, 2013
Appl. No.:
13/866116
Inventors:
Joseph T. Bruder - Ijamsville MD, US
Imre Kovesdi - Rockville MD, US
Duncan L. McVey - Derwood MD, US
Douglas E. Brough - Gaithersburg MD, US
C. Richter King - Washington DC, US
Denise Louise Doolan - Camp Hill, AU
Joao Carlos Aguair - Potomac MD, US
Daniel John Carucci - Washington DC, US
Martha Sedegah - Gaithersburg MD, US
Walter R. Weiss - Bethesda MD, US
Keith Limbach - Gaithersburg MD, US
Imre Kovesdi - Rockville MD, US
Duncan L. McVey - Derwood MD, US
Douglas E. Brough - Gaithersburg MD, US
C. Richter King - Washington DC, US
Denise Louise Doolan - Camp Hill, AU
Joao Carlos Aguair - Potomac MD, US
Daniel John Carucci - Washington DC, US
Martha Sedegah - Gaithersburg MD, US
Walter R. Weiss - Bethesda MD, US
Keith Limbach - Gaithersburg MD, US
International Classification:
G01N 33/50
Abstract:
The invention provides a method of identifying an antigen from a pathogen or a disease antigen comprising the use of an adenoviral vector array comprising two or more different adenoviral vectors, wherein each adenoviral vector comprises a nucleic acid sequence encoding a different antigen of a pathogen. The adenoviral vectors are administered to antigen presenting cells (APCs) in vitro or to an animal in vivo. The immunogenicity of the antigen is measured by screening for an immune response from effector T lymphocytes in vitro and by screening for the absence of pathogen-induced disease onset in vivo.
Plasmodium Falciparum Sporozoite And Liver Stage Antigens
US Patent:
2015026, Sep 24, 2015
Filed:
Mar 19, 2014
Appl. No.:
14/219390
Inventors:
JOAO AGUIAR - ROCKVILLE MD, US
KEITH LIMBACH - GAITHERSBURG MD, US
MARTHA SEDEGAH - GAITHERSBURG MD, US
THOMAS RICHIE - GLENELG MD, US
KEITH LIMBACH - GAITHERSBURG MD, US
MARTHA SEDEGAH - GAITHERSBURG MD, US
THOMAS RICHIE - GLENELG MD, US
International Classification:
A61K 39/015
C07K 14/445
C07K 14/445
Abstract:
The invention provides novel malaria polypeptides expressed at the pre-erythrocytic stage of the malaria life-cycle. The antigens can be utilized to induce an immune response against malaria in a mammal by administering the antigens in vaccine formulations or expressing the antigens in DNA or other nucleic acid expression systems delivered as a vaccine formulation.
Recombinant Polypeptide Construct Comprising Plasmodium Falciparum Circumsporozoite Protein Hla Class I Restricted T-Cell Epitopes
US Patent:
2015012, May 7, 2015
Filed:
Nov 1, 2013
Appl. No.:
14/069656
Inventors:
Martha Sedegah - Gaithersburg MD, US
Thomas Richie - Glenelg MD, US
Thomas Richie - Glenelg MD, US
International Classification:
C07K 7/06
G01N 33/569
G01N 33/569
US Classification:
4241911, 530328, 435 792
Abstract:
The invention relates to a recombinant polypeptide construct comprising epitopes from protein circumsporozoite protein (CSP). The epitopes contain HLA class I binding motifs and stimulate an anti-malaria CD8 T-cell response. The polypeptides can be incorporated into immunogenic formulations against malaria. Additionally, the antigens are useful for facilitating evaluation of immunogenicity of candidate malaria vaccines.
Plasmodium Falciparum Hla Class I Restricted T-Cell Epitopes
US Patent:
2015000, Jan 1, 2015
Filed:
Jun 28, 2013
Appl. No.:
13/930468
Inventors:
Martha Sedegah - Gaithersburg MD, US
Thomas Richie - Glenelg MD, US
Thomas Richie - Glenelg MD, US
International Classification:
G01N 33/50
US Classification:
435 792
Abstract:
The invention relates immunogenic polypeptides and epitopes from protein AMA 1. The epitopes contain HLA class I binding motifs and stimulate an anti-malaria CD8 T-cell response. The polypeptides can be incorporated into immunogenic formulations against malaria. Additionally, the antigens are useful for facilitating evaluation of immunogenicity of candidate malaria vaccines.
NOTICE: You may not use PeopleBackgroundCheck or the information it provides to make decisions about employment, credit, housing or any other purpose that would require Fair Credit Reporting Act (FCRA) compliance. PeopleBackgroundCheck is not a Consumer Reporting Agency (CRA) as defined by the FCRA and does not provide consumer reports.